# NCT02034110 (NCT02034110)

> Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02034110
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Cancer
- Interventions: Dabrafenib; Trametinib
- Enrollment: 206
- Primary outcome: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort
- Primary outcome: Overall Response Rate (ORR) in the Biliary Tract Cancer (BTC) Cohort
- Primary outcome: Overall Response Rate (ORR) in the Gastrointestinal Stromal Tumor (GIST) Cohort
- Primary outcome: Overall Response Rate (ORR) in the Adenocarcinoma of the Small Intestine (ASI) Cohort
- Primary outcome: Overall Response Rate (ORR) in the Low Grade (WHO G1/G2) Glioma (LGG) Cohort
- Primary outcome: Overall Response Rate (ORR) in the High Grade (WHO G3/G4) Glioma (HGG) Cohort
- Primary outcome: Overall Response Rate (ORR) in the Hairy Cell Leukemia (HCL) Cohort
- Primary outcome: Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort

## Indexed commentary on NCT02034110 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02034110